Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC253 in mCRPC
NCT02987829Phase 2Completed
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- May 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trc253 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by TRACON Pharmaceuticals, Inc. Primary endpoint: Dose Limiting Toxicities at 5 weeks. Started May 2017; status: completed.
02
Drugs
trc253
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02987829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987829.